Issue 29

Is North America Losing Its Grip on the Biologics CDMO Market?

Why not sign up for our future email newsletters? Sign up here.

Included in this issue:

LEAD STORY

Is North America's Hold on the Biologics CDMO Market at Risk?

The global biologics market is expected to reach USD 720 bn by 2030, fueled by increasing demand for biologics, biosimilars, and advanced therapies. It is undoubtedly an area of keen interest for CDMOs that specialize in biopharmaceutics. 

Read more here.

FEATURED STORIES

Lonza Sees Strong CDMO Demand and Projects 20% Sales Growth for 2025

Read more here.

Fujifilm Diosynth's USD 8 Billion Expansion Set to Peak in 2025

Read more here.

Upperton Unveils Sterile Manufacturing Facility

Read more here.

Joinn Biologics Acquires Lonza's Guangzhou Facility to Expand Asia-Pacific Presence

Read more here.

Rentschler Biopharma Realigns Strategy to Focus on Biologics

Read more here.

Thermo Fisher Announces Further Job Losses

Read more here.

Ophthalmic Gel Shows Promising Results for Geographic Atrophy Treatment

Read more here.

Touchlight Appoints Industry Veteran Will Downie as Strategic Adviser

Read more here.

Lantheus Acquires Evergreen Theragnostics to Strengthen Radiopharmaceutical Leadership

Read more here.

Catalent and Galapagos Collaborate to Enhance Decentralized CAR-T Manufacturing

Read more here.

Inventage Lab Acquires 40% Stake in Quratis to Boost mRNA Capabilities

Read more here.

Eleva and 3PBIOVIAN Forge Partnership to Increase Production Capacity

Read more here.